NewLink up on human trial of Canada's Ebola vaccine

The Public Health Agency of Canada said a Phase I trial of VSV-EBOV (BPSC-1001), an experimental Ebola vaccine developed at the country's National Microbiology Lab, has begun at the Walter Reed Army Institute of Research in Maryland.

The BioProtection Systems Corp. subsidiary of NewLink Genetics Corp. (NASDAQ:NLNK) has exclusive, worldwide rights to develop and commercialize the recombinant vesicular stomatitis virus (rVSV) vaccine under a 2010 deal. NewLink gained $4.29 (24%) to $22.42 on Monday's news. ...